Literature DB >> 24516004

New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis.

Indira Álvarez-Fernández, Belén Prieto, Verónica Rodríguez, Yolanda Ruano, Ana I Escudero, Francisco V Álvarez.   

Abstract

BACKGROUND: Several studies have revealed a high soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) ratio in preeclamptic women. However, its role in patients with suspected preeclampsia (PE) at triage in the emergency department remains an issue and a controversial unique cutpoint of 85 has been proposed regardless of gestational age. A new cutpoint for sFlt-1/PlGF ratio was investigated to rule out PE at obstetric triage, and to assess its prognostic value for risk of imminent delivery.
METHODS: Blood samples from 257 pregnant women with suspected PE were obtained at obstetric triage admission. Serum PlGF and sFlt-1 were measured by an electrochemoluminiscence immunoassay (ECLIA) on the immunoanalyzer Cobas e601 (Roche Diagnostics) and the corresponding ratio was calculated. Final outcomes (mainly development of PE) were reviewed and time between clinical presentation and delivery was calculated.
RESULTS: The best ratio cutpoint to diagnose PE changed according to gestational age: 23 (92.0% sensitivity, 81.1% specificity) and 45 (83.7% sensitivity, 72.6% specificity) for women <34 and ≥ 34 weeks' gestation, respectively. Furthermore, sFlt-1/PlGF ratio inversely correlated with time elapsed between clinical presentation and delivery, and a cutpoint of 178 could predict complications such as imminent delivery or fetal/neonatal death with a sensitivity of 70.6% and a specificity of 97.8%.
CONCLUSIONS: The new cut-off values for the sFlt-1/PlGF ratio adjusted by the gestational age at clinical presentation can be used to rule out PE at obstetric triage and to predict imminent delivery with better accuracy than the cutpoint currently accepted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24516004     DOI: 10.1515/cclm-2013-0901

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Prediction and prevention of hypertensive disorders of pregnancy.

Authors:  Akihide Ohkuchi; Chikako Hirashima; Kayo Takahashi; Hirotada Suzuki; Shigeki Matsubara
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

2.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

3.  Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia.

Authors:  Evelyn Klein; Dietmar Schlembach; Angela Ramoni; Elena Langer; Franz Bahlmann; Sabine Grill; Helene Schaffenrath; Reinhard van der Does; Diethelm Messinger; Wilma D J Verhagen-Kamerbeek; Manfred Reim; Martin Hund; Holger Stepan
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

4.  Evaluation of Glutathione Peroxidase 4 role in Preeclampsia.

Authors:  Xinguo Peng; Yan Lin; Jinling Li; Mengchun Liu; Jingli Wang; Xueying Li; Jingjing Liu; Xuewen Jia; Zhongcui Jing; Zuzhou Huang; Kaiqiu Chu; Shiguo Liu
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

5.  sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain).

Authors:  A Perales; J L Delgado; M de la Calle; J A García-Hernández; A I Escudero; J M Campillos; M D Sarabia; B Laíz; M Duque; M Navarro; P Calmarza; M Hund; F V Álvarez
Journal:  Ultrasound Obstet Gynecol       Date:  2017-09       Impact factor: 7.299

6.  Abnormal expression and clinical significance of 25-hydroxyvitamin D and sFlt-1 in patients with preeclampsia.

Authors:  Xinhua Chen; Xuxia Xi; Fan Cui; Ming Wen; Aijuan Hong; Zemei Hu; Juan Ni
Journal:  J Int Med Res       Date:  2019-09-12       Impact factor: 1.671

7.  HSPA1L rs1061581 polymorphism is associated with the risk of preeclampsia in Han Chinese women.

Authors:  Jinbao Zong; Yan Lin; Qingwu Tian; Xin Zhao; Kaiqiu Chu; Bing Jiang; Shengjun Li; Guirong Sun; Shiguo Liu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

8.  Role of IL-17 Variants in Preeclampsia in Chinese Han Women.

Authors:  Haiyan Wang; Mingzhen Guo; Fenghua Liu; Jingli Wang; Zheng Zhou; Jing Ji; Yuanhua Ye; Weiqing Song; Shiguo Liu; Bo Sun
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

9.  A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.

Authors:  H Stepan; M Hund; M Gencay; B Denk; C Dinkel; W E Kaminski; P Wieloch; B Semus; T Meloth; L-A Dröge; S Verlohren
Journal:  Hypertens Pregnancy       Date:  2016-03-30       Impact factor: 2.108

10.  Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).

Authors:  D Hayes-Ryan; A S Khashan; K Hemming; C Easter; D Devane; D J Murphy; A Hunter; A Cotter; F M McAuliffe; J J Morrison; F M Breathnach; E Dempsey; L C Kenny; K O'Donoghue
Journal:  BMJ       Date:  2021-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.